UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37355 Viking Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 46-1073877 ( State or other jurisdict ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2022 Results Conference Call February 8, 2023 4:30 AM ET Company Participants Stephanie Diaz - Investor Relations Brian Lian - President and Chief Executive Officer Gregory Zante - Chief Financial Officer Conference Call Participants Joon So Lee - Truist Securities Steven Seedhouse - Raymond James & Associates Joseph Pantginis - H.C. Wainwright Andy Hsieh - William Blair Yale Jen - Laidlaw & Company Scott Henry - ROTH MKM Partners Justin Zelin - BTIG Nazibur Rahman ...

Corporate Presentation November 2022 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' ability to successf ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2022 Earnings Conference Call October 26, 2022 4:30 PM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President & Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Steve Seedhouse - Raymond James Joon Lee - Truist Andy Hsieh - William Blair Thomas Smith - SVB Securities Yale Jen - Laidlaw Scott Henry - ROTH Capital Justin Zelin - BTIG Naz Rahman - Maxim Group Operator Welcome to the Viking T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other j ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2022 Results Conference Call July 27, 2022 4:30 PM ET Company Participants Stephanie Diaz - Manager of Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Steven Seedhouse - Raymond James Joseph Pantginis - H.C. Wainwright Andy Hsieh - William Blair Jay Olson - Oppenheimer Yale Jen - Laidlaw & Company Operator Welcome to the Viking Therapeutics 2022 Second Quarter Financial Results ...

Revenue Generation - The company has not generated any revenue to date and does not expect to receive revenue from drug candidates until regulatory approval and commercialization occur [121]. Research and Development Expenses - Research and development expenses for the year ended December 31, 2021, were $45.0 million, primarily for the VK2809 Phase 2b VOYAGE clinical trial and VK0214 studies [122]. - For the six months ended June 30, 2022, research and development expenses were $26.1 million, focusing on VK2809, VK0214, and VK2735 clinical trials [122]. - Research and development expenses for the three months ended June 30, 2022, increased by 5.8% to $13,542,000 compared to $12,804,000 in 2021, primarily due to increased manufacturing and clinical study expenses [131]. - Research and development expenses for the six months ended June 30, 2022, increased by 7.2% to $26,097,000 from $24,340,000 in 2021, driven by higher manufacturing and clinical study costs [137]. Clinical Trials - The company has completed eight clinical studies for VK2809, enrolling over 300 subjects, with no serious adverse events reported [109]. - VK0214 is in a Phase 1b clinical trial for X-ALD, which was temporarily placed on clinical hold by the FDA in January 2022 but resumed in July 2022 [113]. - VK2735, a dual agonist for metabolic disorders, is undergoing a Phase 1 clinical trial initiated in January 2022 [114]. - VK5211 showed statistically significant increases in lean body mass in a Phase 2 trial with 108 patients recovering from hip fracture surgery [116]. - The impact of the COVID-19 pandemic on clinical trials has caused delays in patient enrollment and site initiation [119]. General and Administrative Expenses - The company expects general and administrative expenses to increase due to hiring, stock-based compensation, and compliance costs associated with being a public company [125]. - General and administrative expenses for the three months ended June 30, 2022, rose by 49.4% to $4,089,000 from $2,737,000 in 2021, mainly due to higher legal services and stock-based compensation costs [133]. - General and administrative expenses for the six months ended June 30, 2022, increased by 43.3% to $7,779,000 from $5,430,000 in 2021, attributed to increased legal services and stock-based compensation [139]. Cash Flow and Financial Position - Cash used in operating activities for the six months ended June 30, 2022, was $23,972,000, a slight decrease from $24,310,000 in 2021 [149]. - Cash provided by investing activities for the six months ended June 30, 2022, was $20,599,000, primarily from investment maturities of $87,000,000, offset by purchases of $66,400,000 [152]. - As of June 30, 2022, the company had cash, cash equivalents, and short-term investments totaling $168.9 million, expected to fund operations through at least September 30, 2023 [143]. - The company anticipates continued losses as it develops drug candidates and seeks regulatory approvals, indicating a need for additional capital in the future [156]. Company Classification - The company is classified as a smaller reporting company and non-accelerated filer, continuing this status until at least December 31, 2023 [127]. Stock Repurchase Program - The company has a stock repurchase program authorized for up to $50.0 million, with 729,034 shares repurchased under the new program as of June 30, 2022 [148].

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Stephanie Diaz – Manager-Investor Relations Brian Lian – President and Chief Executive Officer Greg Zante – Chief Financial Officer Conference Call Participants Jay Olson – Oppenheimer Steven Seedhouse – Raymond James Joe Pantginis – H.C. Wainwright Scott Henry – ROTH Capital Yale Jen – Laidlaw & Company Andy Hsieh – William Blair Justin Zelin – BTIG Operator Good day and welcome to the Vi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other juris ...